We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RAIL3:BMFBOVESPARumo SA Analysis

Data as of 2026-03-14 - not real-time

R$16.26

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Rumo S.A. trades at a price of roughly R$16.26, well below its DCF‑derived fair value of about R$25, indicating a sizable upside potential of over 20%. The stock’s valuation metrics are mixed: a trailing P/E of 35 is above the industry average of 29, yet the dividend yield stands out at nearly 5% with a generous payout ratio that exceeds earnings, raising concerns about sustainability. Technical signals are neutral‑to‑bearish – the 20‑day SMA sits just above the current price, the MACD histogram is marginally negative and the RSI hovers around 53, suggesting limited momentum. However, the low beta of 0.35 points to modest price swings relative to the market, even as 30‑day volatility remains elevated at around 36%.
The balance sheet shows a heavy debt load (debt‑to‑equity >200%) and negative free cash flow, which tempers the attractive dividend and valuation upside. Still, stable trading volumes and solid operating margins (gross ~45%, operating ~39%) provide a cushion. Given the “Greed” sentiment in the fear‑greed index and analyst consensus of a “Buy” with a median target near R$19.5, the stock appears positioned for a rebound if earnings improve and cash generation stabilises.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • MACD bearish crossover and neutral RSI limit upside
  • Price near short‑term support level
  • High volatility may cause price swings

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value suggests ~22% upside
  • Strong operating margins support earnings recovery
  • Analyst consensus and target median above current price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic position in Brazil’s rail logistics infrastructure
  • Potential for dividend policy adjustment as cash flow improves
  • Low beta indicates resilience over longer horizons

Key Metrics & Analysis

Financial Health

Revenue Growth-3.30%
Profit Margin6.12%
P/E Ratio35.3
ROE5.97%
ROA6.88%
Debt/Equity206.85
P/B Ratio2.2
Op. Cash FlowR$7.1B
Free Cash FlowR$-2213816320
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI53.3
SupportR$14.89
ResistanceR$17.40
MA 20R$16.28
MA 50R$15.35
MA 200R$16.03
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair ValueR$25.02
Target PriceR$19.97
Upside/Downside22.80%
GradeUndervalued
TypeValue
Dividend Yield4.98%

Risk Assessment

Beta0.35
Volatility35.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.